Advertisement

Topics

Boehringer Refocuses AD drug on Schizophrenia

07:49 EST 15 Feb 2018 | CHEManager

Boehringer Ingelheim said it plans to shift the focus of its investigational compound BI 409306 to ongoing clinical trials with schizophrenia patients after the drug failed to outperform a placebo in Phase II trials with 450 patients for the indication Alzheimer's disease (AD).

Original Article: Boehringer Refocuses AD drug on Schizophrenia

NEXT ARTICLE

More From BioPortfolio on "Boehringer Refocuses AD drug on Schizophrenia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...